Taletrectinib tissue based companion diagnostic - AnHeart Therapeutics/Foundation medicine
Alternative Names: Taletrectinib FoundationOne®CDx companion diagnostics - AnHeart Therapeutics/Foundation medicineLatest Information Update: 17 Apr 2024
At a glance
- Originator Foundation Medicine
- Developer AnHeart Therapeutics; Foundation Medicine
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Non-small cell lung cancer
Most Recent Events
- 10 Apr 2024 AnHeart Therapeutics has been acquired by Nuvation Bio
- 14 Dec 2023 AnHeart Therapeutics and Foundation medicine agree to develop Taletrectinib tissue based companion diagnostic in USA for Cancer
- 14 Dec 2023 Early research in Non-small cell lung cancer (Diagnosis) in USA (unspecified route)